algeldrate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4250	21645-51-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aluminum hydroxide algeldrate aluminum hydroxide hydrate aluminium hydroxide	A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Molecular weight: 78.00 Formula: AlH3O3 CLOGP: LIPINSKI: None HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: ROTB: 0

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aluminum hydroxide
algeldrate
aluminum hydroxide hydrate
aluminium hydroxide

A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.

Molecular weight: 78.00
Formula: AlH3O3
CLOGP:
LIPINSKI: None
HAC: 3
HDO: 3
TPSA: 60.69
ALOGS:
ROTB: 0

Drug dosage:

Dose	Unit	Route
5	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1983	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	106.36	12.70	88	12455	40783	46632736
Hyponatraemia	97.76	12.70	128	12415	101204	46572315
Schizoaffective disorder	71.18	12.70	23	12520	1429	46672090
Acute kidney injury	66.64	12.70	175	12368	235680	46437839
Drug ineffective	49.67	12.70	66	12477	677772	45995747
Confusional state	44.42	12.70	118	12425	159774	46513745
Sinus rhythm	31.36	12.70	10	12533	595	46672924
End stage renal disease	29.83	12.70	19	12524	5867	46667652
Rhinovirus infection	29.72	12.70	16	12527	3620	46669899
Hepatocellular injury	29.50	12.70	38	12505	29484	46644035
Right aortic arch	29.41	12.70	8	12535	272	46673247
Rheumatoid arthritis	29.25	12.70	14	12529	240201	46433318
Completed suicide	28.55	12.70	3	12540	145917	46527602
Congenital arterial malformation	27.27	12.70	8	12535	359	46673160
Abdominal pain upper	26.88	12.70	93	12450	145212	46528307
Agitation	25.51	12.70	50	12493	55365	46618154
Gastrooesophageal reflux disease	23.86	12.70	58	12485	74286	46599233
Renal injury	23.66	12.70	20	12523	9521	46663998
Clostridium difficile colitis	23.62	12.70	27	12516	18526	46654993
Cutaneous T-cell lymphoma	23.44	12.70	10	12533	1353	46672166
Electrocardiogram QT prolonged	23.25	12.70	46	12497	51279	46622240
Haematemesis	22.62	12.70	33	12510	28773	46644746
Inappropriate antidiuretic hormone secretion	22.28	12.70	23	12520	14079	46659440
Genitourinary symptom	21.91	12.70	5	12538	81	46673438
Dyspepsia	21.53	12.70	53	12490	68419	46605100
Acute left ventricular failure	20.93	12.70	8	12535	815	46672704
Drug hypersensitivity	20.70	12.70	21	12522	243804	46429715
Drug intolerance	20.44	12.70	7	12536	147042	46526477
Vomiting	19.36	12.70	196	12347	452598	46220921
Drug level increased	18.84	12.70	24	12519	18417	46655102
Odynophagia	18.69	12.70	15	12528	6647	46666872
Coma scale abnormal	17.84	12.70	13	12530	4993	46668526
Hepatitis cholestatic	16.57	12.70	14	12529	6663	46666856
Acute pulmonary oedema	16.48	12.70	15	12528	7876	46665643
Morbid thoughts	16.46	12.70	6	12537	536	46672983
Lung disorder	16.32	12.70	36	12507	43268	46630251
False positive investigation result	16.31	12.70	6	12537	550	46672969
Toxicity to various agents	16.04	12.70	20	12523	211746	46461773
Gastritis	15.79	12.70	31	12512	34347	46639172
Drug interaction	15.23	12.70	100	12443	202994	46470525
Pharyngeal paraesthesia	15.04	12.70	7	12536	1163	46672356
Hallucination	15.00	12.70	38	12505	49913	46623606
General physical health deterioration	14.81	12.70	66	12477	115703	46557816
Faeces discoloured	14.31	12.70	20	12523	16767	46656752
Cerebellar haemorrhage	14.19	12.70	7	12536	1322	46672197
Immune thrombocytopenia	14.04	12.70	14	12529	8227	46665292
Melanoderma	14.01	12.70	4	12539	163	46673356
Adrenal mass	13.90	12.70	6	12537	835	46672684
Acute cutaneous lupus erythematosus	13.54	12.70	4	12539	184	46673335
Prurigo	13.39	12.70	6	12537	914	46672605
Pancreatitis acute	13.38	12.70	24	12519	24848	46648671
Troponin T increased	13.33	12.70	6	12537	923	46672596
Acute respiratory failure	13.05	12.70	26	12517	29112	46644407
Antipsychotic drug level increased	13.02	12.70	9	12534	3183	46670336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypophosphataemic osteomalacia	48.98	13.59	10	7104	106	29945258
Hepatocellular injury	36.12	13.59	37	7077	25434	29919930
Chronic kidney disease	33.38	13.59	43	7071	37795	29907569
Mesothelioma	26.26	13.59	8	7106	464	29944900
Gastrooesophageal reflux disease	24.38	13.59	34	7080	32221	29913143
Hypercalciuria	22.68	13.59	6	7108	208	29945156
Craniotabes	22.57	13.59	4	7110	18	29945346
End stage renal disease	18.87	13.59	15	7099	7420	29937944
Hyponatraemic seizure	17.27	13.59	4	7110	79	29945285
Crystal urine	17.18	13.59	4	7110	81	29945283
Violence-related symptom	17.13	13.59	6	7108	541	29944823
Gastrointestinal necrosis	16.28	13.59	10	7104	3279	29942085
IVth nerve paresis	16.20	13.59	3	7111	18	29945346
Lower respiratory tract infection	15.65	13.59	25	7089	26689	29918675
Abdominal pain upper	15.53	13.59	41	7073	62510	29882854
Blood parathyroid hormone decreased	13.95	13.59	5	7109	482	29944882
Dysphagia	13.90	13.59	37	7077	56661	29888703
Toxicity to various agents	13.87	13.59	13	7101	177170	29768194
Blood fibrinogen decreased	13.68	13.59	6	7108	983	29944381

Pharmacologic Action:

Source	Code	Description
ATC	A02AB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
ATC	A02AB02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
MeSH PA	D000276	Adjuvants, Immunologic
MeSH PA	D000863	Antacids
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D007155	Immunologic Factors
CHEBI has role	CHEBI:65265	antacids
CHEBI has role	CHEBI:79314	flame retardants

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Heartburn	indication	16331000
Duodenal ulcer disease	indication	51868009	DOID:1724
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Gastric ulcer	indication	397825006	DOID:10808
Gastric Hypersecretory Conditions	indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.51	acidic
pKa2	4.99	acidic
pKa3	5.47	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
03J11K103C	UNII
4018607	VUID
N0000146920	NUI
D02807	KEGG_DRUG
1330-44-5	SECONDARY_CAS_RN
4017984	VANDF
4018607	VANDF
4019302	VANDF
C0002371	UMLSCUI
CHEBI:33130	CHEBI
CHEMBL3833310	ChEMBL_ID
CHEMBL1200706	ChEMBL_ID
DB06723	DRUGBANK_ID
D000536	MESH_DESCRIPTOR_UI
6328211	PUBCHEM_CID
1945	INN_ID
612	RXNORM
4159	MMSL
5582	MMSL
7537	MMSL
d00978	MMSL
001123	NDDF
007943	NDDF
273944007	SNOMEDCT_US
725733004	SNOMEDCT_US
768557001	SNOMEDCT_US
80399002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Good Sense antacid	HUMAN OTC DRUG LABEL	3	0113-0340	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidRegular Strength	HUMAN OTC DRUG LABEL	3	0113-0357	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidMaximum Strength	HUMAN OTC DRUG LABEL	3	0113-0588	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
good sense antacid	HUMAN OTC DRUG LABEL	3	0113-0851	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Mag-AL Liquid	HUMAN OTC DRUG LABEL	2	0121-1760	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Plus	HUMAN OTC DRUG LABEL	3	0121-1761	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL PlusXS	HUMAN OTC DRUG LABEL	3	0121-1762	SUSPENSION	400 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0094	LIQUID	95 mg	ORAL	OTC monograph final	13 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0095	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
GavisconRegular Strength	HUMAN OTC DRUG LABEL	2	0135-0096	TABLET, CHEWABLE	80 mg	ORAL	NDA	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0574	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINULLL	14 sections
Antacid antigasMaximum Strength	HUMAN OTC DRUG LABEL	3	0363-0528	LIQUID	800 mg	ORAL	OTC MONOGRAPH FINULLL	15 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	12 sections
ADVANCED REGULAR STRENGTH ANTACID	HUMAN OTC DRUG LABEL	3	0363-1639	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-1691	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
REGULAR STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-2628	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
Walgreens Fast Acting Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0363-7630	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
ALMACONE DOUBLE STRENGTH	HUMAN OTC DRUG LABEL	3	0536-0015	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
ALMACONE ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-0025	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
Aluminum Hydroxide	HUMAN OTC DRUG LABEL	1	0536-0091	LIQUID	320 mg	ORAL	OTC monograph final	10 sections
rugby almacone	HUMAN OTC DRUG LABEL	3	0536-1185	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Antacid	Human OTC Drug Label	3	0536-1293	LIQUID	400 mg	ORAL	OTC MONOGRAPH FINULLL	12 sections
REGULAR STRENGTH ANTACID/ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-1317	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID/ ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-1318	SUSPENSION	800 mg	ORAL	OTC monograph final	10 sections
Almacone	HUMAN OTC DRUG LABEL	3	0536-3504	TABLET, CHEWABLE	200 mg	ORAL	OTC monograph final	12 sections
MI-ACID REGULAR STRENGTH	HUMAN OTC DRUG LABEL	3	0904-0004	SUSPENSION	200 mg	ORAL	OTC monograph final	9 sections
MI-ACID MAXIMUM STRENGTH	HUMAN OTC DRUG LABEL	3	0904-0005	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections